bioRxivCancer BiologyPreprint
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6).
C. Ogier, A. M. Charles Solomon, Z. Lu, L. Recoules, A. Klochkova, L. Gabitova-Cornell, B. Bayarmagnai, D. Restifo, A. Surumbayeva, D. B. Vendramini-Costa, A. Deneka, R. Francescone, A. C. Lilly, A. Sipman, J. C. Gardiner, T. Luong, J. Franco-Barraza, N. Ibeme, Q. Cai, M. B. Einarson, E. Nicolas, A. Efimov, E. Megill, N. W. Snyder, C. Bousquet, , I. Astsaturov
Abstract
In pancreatic ductal adenocarcinoma (PDAC), the fibroblastic stroma constitutes most of the tumor mass and is remarkably devoid of functional blood vessels. This raises an unresolved question of how PDAC cells obtain essential metabolites and water-insoluble lipids. We have found a critical role for cancer-associated fibroblasts (CAFs) in obtaining and transferring lipids from blood-borne particles to PDAC cells via trogocytosis of CAF plasma membranes. We have also determined that CAF-expressed phospholipid scramblase anoctamin 6 (ANO6) is an essential CAF trogocytosis regulator required to promote PDAC cell survival. During trogocytosis, cancer cells and CAFs form synapse-like plasma membranes contacts that induce cytosolic calcium influx in CAFs via Orai channels. This influx activates ANO6 and results in phosphatidylserine exposure on CAF plasma membrane initiating trogocytosis and transfer of membrane lipids, including cholesterol, to PDAC cells. Importantly, ANO6-dependent trogocytosis also supports the immunosuppressive function of pancreatic CAFs towards cytotoxic T cells by promoting transfer of excessive amounts of cholesterol. Further, blockade of ANO6 antagonizes tumor growth via disruption of delivery of exogenous cholesterol to cancer cells and reverses immune suppression suggesting a potential new strategy for PDAC therapy.
- organism: mouse
- assay: proteomics
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Conversion of cancer-associated fibroblasts from pro- to antitumor improves the sensitivity of pancreatic cancer to chemotherapeutics
T. Iida, Y. Mizutani, … A. Enomoto·bioRxiv·Jun 29, 2021
- Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer
H. Huang, Z. Wang, … R. A. Brekken·Cancer CellPeer-reviewed·Jun 1, 2022
- Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Zoe X. Malchiodi, Alexander A. Lekan, … Louis M. Weiner·Cancer Immunology ResearchPeer-reviewed·Jul 24, 2026
- Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22
Saumya Y. Maru, Meredith Wetzel, … Elizabeth M. Jaffee·The Journal of ImmunologyPeer-reviewed·Jun 1, 2026
- Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition
George Sharbeen, Joshua A McCarroll, … Phoebe A Phillips·bioRxiv·Jul 12, 2020
- Cancer associated fibroblasts drive epithelial to mesenchymal transition and classical to basal change in pancreatic ductal adenocarcinoma cells with loss of IL-8 expression
Samantha R. Guinn, Brayan Perez, … Jacquelyn W. Zimmerman·bioRxiv·Jan 7, 2025